ClinicalTrials.gg
RecruitingNCT07593079Updated Nov 20, 2026

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

A Phase 2 interventional study of Bicalutamide and Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography in Prostate Cancer, Recurrent Prostate Cancer and Metastatic Prostate Cancer, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Diagnostic

How we know

Updated Nov 20, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies testing bicalutamide in Prostatic Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. bicalutamide · Prostatic Neoplasms.

Planned enrollment
43rd of 54
20 · median 53
Started
2026
with 3 others
Phase 2
18 of 55
3 open now
Registered
54th of 55
by date

Among the 55 studies testing bicalutamide in Prostatic Neoplasms, this one is the 43rd largest by planned enrollment of the 54 interventional ones that give a count, is one of 4 that started in 2026, is one of 18 in phase 2, and was the 54th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

5 of the 55 studies testing bicalutamide in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About bicalutamide

bicalutamide: first FDA approval 1995 (CASODEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing bicalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low levels of PSA. Adult patients with biochemically recurrent prostate cancer (BCR PCa) who have a PSA of less than 1.0 ng/mL and who have undergone complete prostatectomy and/or will be undergoing radiotherapy, in combination with standard of care bicalutamide, will be recruited to this study. Patients will be randomized in a 1:1 ratio into Group A (baseline PSMA PET/CT only with bicalutamide standard of care) or Group B (baseline PSMA PET/CT and an additional PSMA PET/CT after 2 weeks of bicalutamide).

03

Conditions studied

  • Prostate Cancer
  • Recurrent Prostate Cancer
  • Metastatic Prostate Cancer
  • Prostate Cancer Recurrent
  • Prostate Cancer Metastatic

Browse trials for

Keywords

  • Prostate cancer
  • Low PSA
  • PSMA PET
  • BCR
  • Bicalutamide
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed biochemically recurrent prostate cancer, with original diagnosis no more than 2 years from date of consent.
  • Intermediate unfavorable or high-risk prostate cancer.
  • All patients under consideration for radiation therapy, either at the time of first recurrence or in salvage radiation therapy will be included.
  • Patients who have started bicalutamide up to a maximum of 3 days prior to randomization will be allowed to be on protocol. Otherwise, a of at least 42 days will be required.
  • Biological males, at least 18 years of age.
  • Prostate specific antigen (PSA) \< 1.0 ng/mL.
  • Agreement to adhere to Lifestyle Considerations throughout study duration
  • Ability to understand and willingness to sign an IRB approved written document.

Exclusion criteria

Exclusion Criteria:

  • Patients currently on androgen deprivation therapy (ADTs).
  • Currently receiving any other agents.
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to POSLUMA, furosemide, bicalutamide, or other agents used in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Group A: Baseline PSMA PET/CT only with standard of care bicalutamide

    Patients will undergo baseline PSMA PET/CT (PET1) with 18F-rhPSMA-7.3 (F-18 flotufolastat, Posluma). After the 18F-rhPSMA-7.3 injection, patients will undergo research imaging consisting of 5 minutes of PET imaging, followed by routine imaging at 60 minutes after 18F-rhPSMA-7.3 injection. Patients will have blood collected for PROSTest and PSA within 1 day of completion of PET1. Following PET1, patients will initiate standard of care bicalutamide for a minimum of 14 days, with the first dose taken the day after PET1. Patients will undergo a 90 day follow-up visit (relative to PET1) for collection of blood for PROSTest and PSA.

    Drug: Bicalutamide · Device: Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography · Drug: 18F-rhPSMA-7.3 · Diagnostic Test: PROSTest

  • Experimental
    Group B: PSMA PET/CT after 2 weeks of standard of care bicalutamide

    Patients will undergo baseline PSMA PET/CT (PET1) with 18F-rhPSMA-7.3 (F-18 flotufolastat, Posluma). After the 18F-rhPSMA-7.3 injection, patients will undergo research imaging consisting of 5 minutes of PET imaging, followed by routine imaging at 60 minutes after 18F-rhPSMA-7.3 injection. Patients will have blood collected for PROSTest and PSA within 1 day of completion of PET1. Following PET1, patients will initiate standard of care bicalutamide for a minimum of 14 days, with the first dose taken the day after PET1 and will undergo a research PSMA PET/CT (PET2) on Day 14 (±3 days). The research PSMA PET/CT (PET2) will follow the same imaging procedures as the baseline PET. Patients will undergo a 90 day follow-up visit (relative to PET1) for collection of blood for PROSTest and PSA.

    Drug: Bicalutamide · Device: Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography · Drug: 18F-rhPSMA-7.3 · Diagnostic Test: PROSTest

Interventions

  • Bicalutamide is a non-steroidal androgen receptor inhibitor administered as a once a day pill taken orally. This is given as standard of care.

    Also known as: Casodex

  • DeviceProstate-specific membrane antigen Positron Emission Tomography-Computed Tomography

    Patients will undergo prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography (PSMA PET-CT) imaging. Each PSMA PET-CT session will consist of 5 minutes of dynamic imaging conducted via the Biograph Vision Quadra PET-CT, a whole-body PET-CT scanner.

    Also known as: PSMA PET-CT

  • Drug18F-rhPSMA-7.3

    Radioactive diagnostic agent for intravenous use.

    Also known as: Polsuma, Flotufolastat F-18

  • Diagnostic testPROSTest

    PROSTest is a novel, blood-based qPCR assay that assesses gene expression to diagnose PCa and predict patient outcomes to different treatments.

06

What researchers measure

Primary outcomes

  1. Group B only: Lesion detection rates between PET1 and PET2.

    Differences in lesion detection rates between Group B PET1 and PET2 will be analyzed by McNemar's test. Lesion detection rates will be reported by Group B patients at PET1 and PET2 scans and by the two scan sets (first 5 minutes and at 60 minutes post 18F-rhPSMA-7.3 injection).

    Time frame: Baseline and 14 days after start of bicalutamide treatment (total estimated time 14 days)

Secondary outcomes

  1. Group A and B: Number of lesions detected on early scan versus delayed scan

    The total number of lesions detected per patient will be summarized as counts. The number of lesions will be summarized by descriptive statistics for all patients at PET1, Group A patients at PET1, Group B patients at PET1, and Group B patients at PET2 and for each, by the two scan sets (early scan = first 5 minutes and at delayed scan = 60 minutes post 18F-rhPSMA-7.3 injection).

    Time frame: At baseline and 14 days after start of bicalutamid treatment (total estimated time is 14 days)

  2. Group A and B: Correlation between PSA response and PROSTest after radiation therapy

    The correlation between PSA response and PROSTest after radiation therapy will be analyzed in Group A versus Group B. The results will be reported as a two-sample t-test or Wilcoxon sum rank test.

    Time frame: Through day 90

  3. Group A and B: Comparison of PSA response in patients who are treated with radiation vs. those treated with radiation

    The comparison of PSA response will be analyzed in patients who are treated with radiation based on results of the PET2 versus those treated with radiation based on the results of PET1. The comparison will be reported as the results of a two-sample t-test or Wilcoxon sum rank test.

    Time frame: Through day 90

  4. Group B only: Correlation between PSA kinetics and detection rates between PET1 and PET2

    The correlation between PSA kinetics and detection rates will be reported as the results of a two sample t-test or Wilcoxon sum rank test for each timepoint, PET1 and PET2.

    Time frame: Through day 90

  5. Group B only: Correlation between PROSTest results and detection rates of PET1 and PET2

    Correlation between PROSTest results and detection rates of PET1 and PET2 will be reported as two sample t-test or Wilcoxon sum rank test. Results will be reported for PET1 and PET2.

    Time frame: 14 days after start of bicalutamide treatment (total estimated time 14 days)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Vikas Prasad, MD, PhD · Contactpvikas@wustl.edu · 314-632-2812
    • Vikas Prasad, MD, PhD · Principal investigator
    • Farrokh Dehdashti, MD · Sub investigator
    • Jeff Michalski, MD · Sub investigator
    • Jingqin (Rosy) Luo, PhD · Sub investigator
    • Jade Tao, PhD · Sub investigator
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Dec 2027, 12 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 12 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 20, 2026: start Oct 2026 → Nov 2026, primary completion Nov 2027 → Dec 2027 and completion Jan 2028 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 18, 2026
StartActual
Nov 16, 2026was Oct 2026
Primary completionEst.
Dec 14, 2027was Nov 2027
CompletionEst.
Feb 28, 2028was Jan 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
Washington University School of Medicine is now Recruiting
Nov 20, 2026
Start date
Oct 31, 2026→Nov 16, 2026 (actual)
Nov 20, 2026
Primary completion
Nov 14, 2027→Dec 14, 2027
Nov 20, 2026
Study completion
Jan 31, 2028→Feb 28, 2028
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    Washington University School of Medicine is now Recruiting
    Start date Oct 31, 2026→Nov 16, 2026 (now actual)
    Primary completion Nov 14, 2027→Dec 14, 2027
    Study completion Jan 31, 2028→Feb 28, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07593079
Collaborators
The Society of Nuclear Medicine and Molecular Imaging
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Nov 16, 2026
Primary completion
Dec 14, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Vikas Prasad, MD, PhD
Contact
pvikas@wustl.edu
314-632-2812
Vikas Prasad, MD, PhD
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bicalutamide

Start the discussion